United Maritime Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

United Maritime Capital’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$243K	–	48
2021 Q4	$243K	Sell	3,000 -3,000	-50%	-$257K	0.28%	49
2021 Q3	$570K	Sell	6,000 -1,000	-14%	-$101K	0.63%	38
2021 Q2	$690K	Sell	7,000 -2,000	-22%	-$175K	0.52%	35
2021 Q1	$752K	Hold	9,000	–	–	0.62%	32
2020 Q4	$777K	Buy	+9,000	New	+$697K	0.67%	28

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

United Maritime Capital's BIB Position: Q1 2022 in Review

United Maritime Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2022, closing a stake of 3,000 shares — an estimated $243K sold.

United Maritime Capital first reported a position in BIB in Q4 2020 and held it in 5 quarters. The position peaked at $777K in Q4 2020. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2022.

United Maritime Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2022 after selling out during the quarter.
United Maritime Capital sold 3,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2022, an estimated $243K.
United Maritime Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2020 and held it in 5 quarters.
United Maritime Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $777K in Q4 2020.
28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2022.

Based on United Maritime Capital's 13F filing for Q1 2022, filed 12 May 2022.